Clearside Biomedical

Clearside Biomedical R&D per Employee

Delisted

The R&D Spending per Employee of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 563,333.33 USD. In the previous year, R&D Spending per Employee was 631,696.97 USD — a change of -10.82% (lower).

R&D per Employee

563,333.33USD

YoY

-10.82%

Last updated:

R&D Spending per Employee of Clearside Biomedical is 2024 563,333.33 USD. R&D Spending per Employee of Clearside Biomedical was 2023 631,696.97 USD. It decreases by -10.82% lower compared to the previous year.

The Clearside Biomedical R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2017
1.49 M USD
Jan 1, 2018
2.07 M USD
Jan 1, 2019
474,545.45 USD
Jan 1, 2020
456,666.67 USD
Jan 1, 2021
561,818.18 USD
Jan 1, 2022
594,848.48 USD
Jan 1, 2023
631,696.97 USD
Jan 1, 2024
563,333.33 USD
The Clearside Biomedical R&D per Employee history
YEARR&D per EmployeeYoY
563,333.33USD-10.82%
631,696.97USD+6.19%
594,848.48USD+5.88%
561,818.18USD+23.03%
456,666.67USD-3.77%
474,545.45USD-77.07%
2.07 MUSD+39.23%
1.49 MUSD+152.06%
589,696.97USD+80.86%
326,060.61USD+60.84%
202,727.27USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

R&D Spending per Employee of Clearside Biomedical is 563,333.33 USD in 2024.

R&D Spending per Employee of Clearside Biomedical changed from 631,696.97 USD to 563,333.33 USD, representing a -10.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Clearside Biomedical

All Key Metrics — Clearside Biomedical